NCT01602588

A Randomised Trial Investigating the Additional Benefit of Hydroxychloroquine(HCQ)to Short Course Radiotherapy (SCRT) in Patients Aged 70 Years and Older With High Grade Gliomas (HGG)

A Randomised Phase 2 Trial Investigating the Additional Benefit of Hydroxychloroquine(HCQ)to Short Course Radiotherapy (SCRT) in Patients Aged 70 Years and Older With High Grade Gliomas (HGG)

• Status: Completed
• Phase: Phase 2
• Study type: Interventional
• Enrollment: 54 (actual)
• Sponsor: University College, London · Academic / Other
• Sex: All
• Age: 70 Years – 100 Years
• Healthy volunteers: Not accepted

Summary

There is emerging evidence that hydroxychloroquine (HCQ), a drug used commonly in the prevention/ treatment of malaria, rheumatoid arthritis and lupus erythematosus, may improve survival outcome in a variety of cancers including HGG, with few side effects. In this trial the investigators wish to investigate whether treatment with radiotherapy and hydroxychloroquine is more effective than treatment with radiotherapy alone.

Conditions

• Glioblastoma

Interventions

Type	Name	Description
DRUG	Hydroxychloroquine	200mg bd from 14 days post surgery until clinical or radiological progression
RADIATION	Radiotherapy	Short Course radiotherapy

Timeline

• Start date: 2013-05-01
• Primary completion: 2016-10-01
• Completion: 2017-11-01
• First posted: 2012-05-21
• Last updated: 2018-05-03

Locations

15 sites across 1 country: United Kingdom